Latest News
Category: ASX
Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate...
Read more
Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent...
Read more
Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)...
Read more
Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder...
Read more
Telix today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of...
Read more
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August...
Read more
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of...
Read more
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June...
Read more
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer...
Read more
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging...
Read more